Brian M. Strem - 21 Oct 2021 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role: President and CEO, Director
Signature: /s/ Sarah Romano, Attorney-in-Fact*
Issuer symbol: KPRX
Transactions as of: 21 Oct 2021
Net transactions value: +$25,173
Form type: 4
Filing time: 22 Nov 2021, 15:35:41 UTC
Previous filing: 02 Aug 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPRX	Common Stock	Award		+9,517			9,517	21 Oct 2021	Direct	F1
transaction	KPRX	Common Stock	Purchase	$25,173	+17,853	+188%	$1.41	27,370	18 Nov 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Content

Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.